<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0004936'>Venous thrombosis</z:hpo> typically involves the lower extremity circulation </plain></SENT>
<SENT sid="1" pm="."><plain>Rarely, it can occur in the cerebral or splanchnic veins and these are the most frightening manifestations because of their high mortality rate </plain></SENT>
<SENT sid="2" pm="."><plain>A third site of rare <z:hpo ids='HP_0004936'>venous thrombosis</z:hpo> is the deep system of the upper extremities that, as for the lower extremity, can be complicated by <z:hpo ids='HP_0002204'>pulmonary embolism</z:hpo> and <z:e sem="disease" ids="C0032807" disease_type="Disease or Syndrome" abbrv="">post-thrombotic syndrome</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>The authors conducted a narrative review focused on clinical manifestations, risk factors, and treatment of rare venous thromboses </plain></SENT>
<SENT sid="4" pm="."><plain>Local risk factors such as <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> or <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> are frequent in <z:mp ids='MP_0005048'>thrombosis</z:mp> of cerebral or portal veins </plain></SENT>
<SENT sid="5" pm="."><plain>Upper extremity <z:hpo ids='HP_0002625'>deep-vein thrombosis</z:hpo> is mostly due to local risk factors (catheter- or effort-related) </plain></SENT>
<SENT sid="6" pm="."><plain>Common systemic risk factors for rare venous thromboses are inherited <z:hpo ids='HP_0100724'>thrombophilia</z:hpo> and oral contraceptive use; <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloproliferative <z:hpo ids='HP_0002664'>neoplasms</z:hpo> are closely associated with splanchnic vein <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
<SENT sid="7" pm="."><plain>In the <z:hpo ids='HP_0011009'>acute</z:hpo> phase rare venous thromboses should be treated conventionally with low-molecular-weight <z:chebi fb="5" ids="28304">heparin</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain>Use of local or systemic fibrinolysis should be considered in the case of clinical deterioration in spite of adequate anticoagulation </plain></SENT>
<SENT sid="9" pm="."><plain>Anticoagulation with <z:chebi fb="6" ids="28384">vitamin K</z:chebi>-<z:chebi fb="68" ids="48706">antagonists</z:chebi> is recommended for 3-6 months after a first episode of rare <z:hpo ids='HP_0004936'>venous thrombosis</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>Indefinite anticoagulation is recommended for <z:hpo ids='HP_0002639'>Budd-Chiari syndrome</z:hpo>, <z:hpo ids='HP_0004419'>recurrent thrombosis</z:hpo> or unprovoked <z:mp ids='MP_0005048'>thrombosis</z:mp> and permanent risk factors </plain></SENT>
<SENT sid="11" pm="."><plain>In conclusion, the progresses made in the last couple of decades in diagnostic imaging and the broadened knowledge of thrombophilic abnormalities improved the recognition of rare venous thromboses and the understanding of pathogenic mechanisms </plain></SENT>
<SENT sid="12" pm="."><plain>However, the recommendations for treatment mainly derive from observational studies </plain></SENT>
</text></document>